NDAORALSOLUTION
Approved
Apr 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Mechanism of Action
unknown, it is thought to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. The effect of rivastigmine may lessen as the disease process advances…
Clinical Trials (3)
16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients
Started Aug 2014
222 enrolled
Alzheimer's Disease
A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease
Started Apr 2010
51 enrolled
Alzheimer's Disease
Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)
Alzheimer DiseaseCognition Disorders